Without fibrinogen bridging, platelets cannot aggregate properly, which reduces thrombus formation very effectively.37 GPIIb/IIIa inhibitors induce a more potent antiplatelet effect than P2Y12 inhibitors.34 However, the high potency comes with increased risks of bleeding and thrombocytopenia.38–42 Of note, abciximab and eptifibatide are no longer available on the market, leaving tirofiban as the remaining GPIIb/IIIa. The gene discussed is ITGA2B; the disease is Thrombocytopenia.